Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

Autor: Marion Vandromme, Jean Philippe Spano, Olivier Cussenot, Chloé Rideau, Carole Corsini, Isabelle Treilleux, Michèle Vintraud, Ignace Vergote, Yves-Jean Bignon, Kevin S. Hughes, Bernard Baertschi, Eitan Friedman, Daniel Zarca, Marie Duboys de Labarre, Pascal Pujol, Jean Marc Rey, Joseph Gligorov, Ettore D. Capoluongo, Clarisse Duriez, Marion Imbert-Bouteille, Yann Neuzillet, Jean-Louis Mandel, Isabelle Ray-Coquard, Laurence Gladieff, Jose E. Alés Martínez, Frédérique Penault-Llorca, Karim Fizazi, Pierre Jean Lamy, Julie A. Vendrell, Pascal Hammel, Thibault De La Motte Rouge, Jesus Garcia Foncillas, Diether Lambrechts, Tatiana Kogut-Kubiak, Karen Baudry, William Jacot, William D. Foulkes, Frédéric Thomas, Sophie Nambot, Massimo Barberis, Michèle Anahory, Matti Aapro, Xavier Rebillard, Josep M. Piulats, Florence Duchamp, Steven A. Narod, Sylviane Olschwang, Banu Arun, Marc Bollet, Philp Beer, Clare Turnbull, Helen Hanson, Nicola Normanno, Virginie Galibert

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
European Journal of Cancer
European Journal of Cancer, 2021, 146, pp.30-47. ⟨10.1016/j.ejca.2020.12.023⟩
European Journal of Cancer, Elsevier, 2021, 146, pp.30-47. ⟨10.1016/j.ejca.2020.12.023⟩

BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d68784e83fff96e28dfb34c7477a991a
http://hdl.handle.net/2445/176353